Depression treatments that are available today are the result of decades of research.
Are you currently struggling with depression?
Have you been unable to find relief with standard antidepressant medication?
The Depression Clinical and Research Program at Massachusetts General Hospital is seeking patients with major depressive disorder (MDD) between the ages of 18 and 65 to participate in a new depression research study. This study is testing whether the combination of the drugs brexpiprazole and intranasal ketamine can safely and effectively treat people who are already taking an antidepressant medication, but have not had a satisfactory response.
Ketamine is approved by the U.S. Food and Drug Administration (FDA) to be used with other drugs for anesthesia and as a pain reliever during procedures. However, ketamine is not approved by the FDA to treat depression. Brexpiprazole (Rexulti) is approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).
Participants will receive either the active study medication (1/2 chance of receiving brexpiprazole) plus 40 mg of ketamine administered intranasally, or placebo (1/2 chance of receiving placebo) plus 40 mg of ketamine administered intranasally. Participants will be monitored by an experienced study physician. The study requires 12 visits to our research clinic over approximately one month. Please contact us if you or someone you know is interested in learning more about this study. Participants will receive compensation for their time.
If you are interested in learning more about this study, please contact Taquesha at 617-724-3520 or at TDEAN4@mgh.harvard.edu.